Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAFFR-CAR T cells in relapsed/refractory B-cell NHL
NCT05370430Phase 1Recruiting
- Sponsor
- PeproMene Bio, Inc.
- Start
- Jun 2022
- Primary completion
- Jul 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PMB-101 in B-cell non-Hodgkin lymphoma, sponsored by PeproMene Bio, Inc. Primary endpoints: Adverse Events at 1 year and Maximum Tolerated Dose at 28 days. Started Jun 2022; status: recruiting.
02
Drugs
PMB-101
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05370430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05370430.